Default company panoramic image
F563e415 4ad9 4344 853e 6bb1b06df053

Galactica Pharmaceuticals, Inc.

Developing a proprietary novel RAGE fusion protein, initially for the treatment of diabetes and diabetic complications.

  • Stage Concept Only
  • Industry Biotechnology
  • Location West Conshohocken, PA, USA
  • Currency USD
  • Employees 1

Company Summary

Galactica's RAGE protein is the first molecule of any type to have demonstrated in vivo efficacy against at least two major diabetic complications - retinopathy and neuropathy. This is of enormous clinical significance, as many diabetics initially present with one major complication but subsequently develop multiple complications over time. In the U.S. alone, we spend over $200 billion per year taking care of diabetics.



  • Default avatar
    Harkins Cunningham LLP
    Default avatar
    Chernow, Kurtzman and Company, P.C.

Previous Investors

  • Default avatar
    The Company has been self-funded by the founder and CEO and immediate family members |to date.|